Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms

• Janin Chandra,
• Morten Hansen,
• Nathalie Labarriere,
• Nathalie Labarriere,
• Ilaria Marigo,
• Ilaria Marigo,
• Fernando Souza-Fonseca-Guimaraes,
• Lazar Vujanovic,
• Lazar Vujanovic,
• Yoshinobu Koguchi,
• Nicolas Jacquelot

Affiliations

Janin Chandra

The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia

Morten Hansen

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Nathalie Labarriere

Nantes Université, Université Angers, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302., Nantes, France

Nathalie Labarriere

LabEx IGO, Université de Nantes, Nantes, France

Ilaria Marigo

Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

Ilaria Marigo

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

Fernando Souza-Fonseca-Guimaraes

The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia

Lazar Vujanovic

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States

Lazar Vujanovic

Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States

Yoshinobu Koguchi

Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States

Nicolas Jacquelot

0Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada